# Meta-Layer Methodology Documentation

This directory contains documentation for the various methodological approaches being developed for alternative splice site prediction.

## Document Index

| Document | Description | Status |
|----------|-------------|--------|
| [ROADMAP.md](ROADMAP.md) | High-level methodology development roadmap | Active |
| [APPROACH_A_PAIRED.md](APPROACH_A_PAIRED.md) | Siamese/paired delta prediction | Tested (r=0.38) |
| [APPROACH_B_SINGLE_PASS.md](APPROACH_B_SINGLE_PASS.md) | Single-pass validated delta prediction | **BEST (r=0.507)** â­ |
| [MULTI_STEP_FRAMEWORK.md](MULTI_STEP_FRAMEWORK.md) | Decomposed classification approach | â­ **Best for Interpretability** |
| [GPU_REQUIREMENTS.md](GPU_REQUIREMENTS.md) | Compute resource guide | Active |

---

## ğŸ† Method Selection Guide

### TL;DR: Which Method to Use?

| Your Goal | Best Method | Why |
|-----------|-------------|-----|
| **"Should I investigate this variant?"** | Multi-Step Step 1 | Direct yes/no answer |
| **"What kind of effect is this?"** | Multi-Step Step 2 | Donor gain/loss, Acceptor gain/loss |
| **"Where should I target my ASO?"** | Multi-Step Step 3 | Position localization |
| **"How strong is the effect?"** | ValidatedDelta | Continuous delta scores |
| **"Rank variants by severity"** | ValidatedDelta | Quantitative ranking |
| **"Explain to FDA/stakeholders"** | Multi-Step | Interpretable decision trail |

### Two Complementary Approaches

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                    CHOOSING YOUR APPROACH                                â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                          â”‚
â”‚  MULTI-STEP FRAMEWORK â­ (For Decisions & Interpretation)               â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€               â”‚
â”‚  âœ… "Is this pathogenic?"                                               â”‚
â”‚  âœ… "What type of effect?"                                              â”‚
â”‚  âœ… "Where exactly?"                                                    â”‚
â”‚  âœ… Explainable to regulators                                           â”‚
â”‚  âš ï¸ Step 1 needs improvement (AUC=0.61 â†’ need >0.75)                   â”‚
â”‚                                                                          â”‚
â”‚  VALIDATEDDELTA â­ (For Quantification & Ranking)                       â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                       â”‚
â”‚  âœ… r=0.507 correlation (best quantitative)                             â”‚
â”‚  âœ… Continuous delta scores                                              â”‚
â”‚  âœ… Rank variants by effect magnitude                                   â”‚
â”‚  âš ï¸ Requires threshold for yes/no decisions                            â”‚
â”‚                                                                          â”‚
â”‚  RECOMMENDED: Use BOTH together for comprehensive analysis              â”‚
â”‚                                                                          â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

## Quick Reference

### Approach Summary

```
APPROACH A (Paired)               APPROACH B (Single-Pass) â­ BEST
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€         â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
ref_seq â”€â”€â†’ encoder â”€â”€â”           alt_seq â”€â”€â†’ encoder â”€â”€â”
                      â”œâ”€â†’ diff    ref_base â”€â”€â†’ embed â”€â”€â”¼â”€â†’ delta
alt_seq â”€â”€â†’ encoder â”€â”€â”˜           alt_base â”€â”€â†’ embed â”€â”€â”˜

Target: base_delta                Target: validated_delta
Status: r=0.38                    Status: r=0.507 (8K samples) â­


TARGET FORMAT (Both Approaches):
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
target = [Î”_donor, Î”_acceptor, Î”_neither]  # continuous floats in [-1, 1]
Example: [+0.35, -0.02, -0.33] = donor gain (+0.35)

Validated targets (Approach B):
  Splice-altering: target = base_model(alt) - base_model(ref)  # Trust base model
  Normal:          target = [0.0, 0.0, 0.0]                    # Override!


MULTI-STEP FRAMEWORK
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
Step 1: Is splice-altering? â†’ Binary (AUC=0.61, needs >0.7)
Step 2: What type?          â†’ Multi-class (NOT IMPLEMENTED)
Step 3: Where?              â†’ Localization (NOT IMPLEMENTED)
Step 4: How strong?         â†’ Regression (NOT IMPLEMENTED)
```

### Key Differences

| Aspect | Approach A | Approach B | Multi-Step |
|--------|------------|------------|------------|
| Input | ref + alt | alt + var_info | alt + var_info |
| Target | base_delta | validated_delta | classification |
| Forward passes | 2 | 1 | 1-4 |
| Interpretability | Low | Medium | High |

## Current Status

| Method | Correlation | Status | Recommended |
|--------|-------------|--------|-------------|
| Paired Prediction (A) | r=0.38 | Tested | No |
| **Validated Single-Pass (B)** | **r=0.507** | â­ **BEST** | **Yes** |
| Binary Classification | AUC=0.61 | Needs improvement | For triage |

**Key Finding**: More data significantly helps. 8000 samples improved correlation by +24%.

## Priority

1. âœ… **DONE**: Validated Single-Pass with 8K samples â†’ r=0.507
2. **HIGH**: Scale to full SpliceVarDB (50K samples) on GPU â†’ Expected: r>0.60
3. **HIGH**: HyenaDNA encoder (GPU required)
4. **MEDIUM**: Improve Binary Classification (F1 > 0.7)
5. **LOW**: Multi-Step Steps 2-4

---

## ğŸ¯ Application to RNA Therapeutics

### Which Methods Are Most Promising?

| Method | Triage | Effect Type | Position | Quantification | Explainability |
|--------|--------|-------------|----------|----------------|----------------|
| **Multi-Step** â­ | âœ… Best | âœ… Best | âœ… Best | âš ï¸ Indirect | âœ… **Best** |
| **ValidatedDelta** â­ | âš ï¸ Threshold | âš ï¸ Derived | âš ï¸ Max pos | âœ… Best | âš ï¸ Numbers only |
| Paired Delta (A) | âš ï¸ Poor | âš ï¸ Derived | âš ï¸ Noisy | âš ï¸ r=0.38 | âŒ Poor |

### Why Multi-Step is Critical for Drug Discovery

1. **Regulatory Approval**: FDA requires mechanistic understanding
   - âœ… "This variant is pathogenic because it creates a new donor site at position 127"
   - âŒ "Î”_donor = 0.35" (what does this mean?)

2. **ASO Target Design**: Need to know WHERE to target
   - âœ… Multi-Step Step 3 gives position localization
   - âŒ ValidatedDelta gives max delta position (indirect)

3. **Clinical Decisions**: Binary yes/no for treatment decisions
   - âœ… Multi-Step: "P(splice-altering) = 0.92 â†’ TREAT"
   - âŒ ValidatedDelta: "Î” = 0.35 â†’ ??? â†’ need threshold â†’ TREAT?"

### Recommended Workflow: Combined Approach

```
RNA THERAPEUTICS VARIANT SCREENING PIPELINE
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€

â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚  PHASE 1: TRIAGE (Multi-Step Step 1)                                    â”‚
â”‚  Input:  10,000 candidate variants                                      â”‚
â”‚  Filter: P(splice-altering) > 0.5                                       â”‚
â”‚  Output: 1,000 high-priority variants                                   â”‚
â”‚  Time:   ~1 minute                                                      â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                               â†“
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚  PHASE 2: EFFECT TYPING (Multi-Step Step 2)                             â”‚
â”‚  Input:  1,000 high-priority variants                                   â”‚
â”‚  Output: Classified by effect type                                      â”‚
â”‚    - 400 Donor gain (new cryptic donors)                                â”‚
â”‚    - 200 Donor loss (exon skipping)                                     â”‚
â”‚    - 250 Acceptor gain/loss                                             â”‚
â”‚    - 150 Complex                                                        â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                               â†“
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚  PHASE 3: QUANTIFICATION (ValidatedDelta)                               â”‚
â”‚  Input:  1,000 classified variants                                      â”‚
â”‚  Output: Delta scores [Î”_donor, Î”_acceptor]                             â”‚
â”‚  Use:    Rank by |Î”| for prioritization                                 â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                               â†“
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚  PHASE 4: LOCALIZATION (Multi-Step Step 3) [FUTURE]                     â”‚
â”‚  Input:  Top 100 candidates (by delta magnitude)                        â”‚
â”‚  Output: Exact affected positions Â± 5nt                                 â”‚
â”‚  Use:    Design 18-25mer ASO targeting this position                    â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                               â†“
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚  PHASE 5: EXPERIMENTAL VALIDATION                                       â”‚
â”‚  Methods: RNA-seq, minigene assays, RT-PCR                              â”‚
â”‚  Top 10 candidates â†’ wet lab                                            â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### Limitations & Next Steps

| Limitation | Impact | Solution | Priority |
|------------|--------|----------|----------|
| Step 1 AUC=0.61 | Triage accuracy | More data, HyenaDNA | â­ HIGH |
| Step 2 not tested | No effect typing | Run experiments | MEDIUM |
| Step 3 not implemented | No localization | Build model | â­ HIGH |
| r=0.507 for ValidatedDelta | ~50% variance explained | Scale to 50K | HIGH |

---

## Related Documentation

- `../experiments/` - Detailed experiment logs
- `../experiments/004_validated_delta/` - Best results
- `../LABELING_STRATEGY.md` - Label derivation strategies
- `../ARCHITECTURE.md` - Model architectures

